STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more

The FDA has approved an oral treatment for advanced multiple myeloma called Zenbexus, which is the first drug cleared by U.S. regulators using a more sensitive measure of remission. This new drug belongs to a new class of blood cancer drugs called CELMoDs, which work by redirecting a cell's natural machinery to eliminate cancer-causing proteins.

In other news, a U.S. appeals court ruled that a lower-court judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs. The court decided that UMB Bank was entitled to represent Celgene shareholders as a trustee despite an error in how it was appointed.

Brief written by urgent.news from STAT News's own syndicated text. Machine-written — it may contain errors, so check the original before relying on it.